Revvity Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectio… Read more
Revvity Inc. (RVTY) - Net Assets
Latest net assets as of December 2025: $7.25 Billion USD
Based on the latest financial reports, Revvity Inc. (RVTY) has net assets worth $7.25 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.17 Billion) and total liabilities ($4.92 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.25 Billion |
| % of Total Assets | 59.58% |
| Annual Growth Rate | 9.35% |
| 5-Year Change | 1.53% |
| 10-Year Change | 236.67% |
| Growth Volatility | 21.34 |
Revvity Inc. - Net Assets Trend (1985–2025)
This chart illustrates how Revvity Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Revvity Inc. (1985–2025)
The table below shows the annual net assets of Revvity Inc. from 1985 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.25 Billion | -5.43% |
| 2024-12-31 | $7.67 Billion | -2.61% |
| 2023-12-31 | $7.87 Billion | +6.64% |
| 2022-12-31 | $7.38 Billion | +3.38% |
| 2021-12-31 | $7.14 Billion | +91.17% |
| 2020-12-31 | $3.74 Billion | +32.75% |
| 2019-12-31 | $2.81 Billion | +8.85% |
| 2018-12-31 | $2.58 Billion | +3.27% |
| 2017-12-31 | $2.50 Billion | +16.23% |
| 2016-12-31 | $2.15 Billion | +2.04% |
| 2015-12-31 | $2.11 Billion | +3.35% |
| 2014-12-31 | $2.04 Billion | +2.39% |
| 2013-12-31 | $1.99 Billion | +2.82% |
| 2012-12-31 | $1.94 Billion | +5.30% |
| 2011-12-31 | $1.84 Billion | -4.32% |
| 2010-12-31 | $1.93 Billion | +18.20% |
| 2009-12-31 | $1.63 Billion | +3.89% |
| 2008-12-31 | $1.57 Billion | -0.47% |
| 2007-12-31 | $1.58 Billion | -0.16% |
| 2006-12-31 | $1.58 Billion | -4.41% |
| 2005-12-31 | $1.65 Billion | +13.04% |
| 2004-12-31 | $1.46 Billion | +8.23% |
| 2003-12-31 | $1.35 Billion | +7.72% |
| 2002-12-31 | $1.25 Billion | -8.16% |
| 2001-12-31 | $1.36 Billion | +87.20% |
| 2000-12-31 | $728.39 Million | +32.24% |
| 1999-12-31 | $550.80 Million | +37.80% |
| 1998-12-31 | $399.70 Million | +21.75% |
| 1997-12-31 | $328.30 Million | -10.08% |
| 1996-12-31 | $365.10 Million | -0.49% |
| 1995-12-31 | $366.90 Million | -17.62% |
| 1994-12-31 | $445.40 Million | -6.72% |
| 1993-12-31 | $477.50 Million | +0.82% |
| 1992-12-31 | $473.60 Million | +12.57% |
| 1991-12-31 | $420.70 Million | +13.83% |
| 1990-12-31 | $369.60 Million | +5.90% |
| 1989-12-31 | $349.00 Million | +5.03% |
| 1988-12-31 | $332.30 Million | +22.44% |
| 1987-12-31 | $271.40 Million | +14.85% |
| 1986-12-31 | $236.30 Million | +16.18% |
| 1985-12-31 | $203.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Revvity Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3391.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $6.05 Billion | 83.50% |
| Other Components | $1.20 Billion | 16.50% |
| Total Equity | $7.25 Billion | 100.00% |
Revvity Inc. Competitors by Market Cap
The table below lists competitors of Revvity Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Oriental Education & Technology
NYSE:EDU
|
$8.97 Billion |
|
Wärtsilä Oyj Abp
PINK:WRTBF
|
$8.97 Billion |
|
Daiwa Securities Group Inc
PINK:DSECF
|
$8.97 Billion |
|
Dycom Industries Inc
NYSE:DY
|
$8.98 Billion |
|
Generac Holdings Inc
NYSE:GNRC
|
$8.97 Billion |
|
Interpublic Group of Cos.
LSE:0JCK
|
$8.96 Billion |
|
APA CORP. DL -625
F:2S3
|
$8.95 Billion |
|
Lens Technology Co Ltd
SHE:300433
|
$8.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Revvity Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,666,874,000 to 7,250,360,000, a change of -416,514,000 (-5.4%).
- Net income of 241,675,000 contributed positively to equity growth.
- Dividend payments of 32,799,999 reduced retained earnings.
- Share repurchases of 820,815,000 reduced equity.
- Other comprehensive income increased equity by 396,105,000.
- Other factors decreased equity by 200,679,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $241.68 Million | +3.33% |
| Dividends Paid | $32.80 Million | -0.45% |
| Share Repurchases | $820.82 Million | -11.32% |
| Other Comprehensive Income | $396.11 Million | +5.46% |
| Other Changes | $-200.68 Million | -2.77% |
| Total Change | $- | -5.43% |
Book Value vs Market Value Analysis
This analysis compares Revvity Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 46.01x to 1.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $1.90 | $87.37 | x |
| 1986-12-31 | $2.18 | $87.37 | x |
| 1987-12-31 | $2.45 | $87.37 | x |
| 1988-12-31 | $2.78 | $87.37 | x |
| 1989-12-31 | $3.00 | $87.37 | x |
| 1990-12-31 | $3.25 | $87.37 | x |
| 1991-12-31 | $3.78 | $87.37 | x |
| 1992-12-31 | $4.21 | $87.37 | x |
| 1993-12-31 | $4.24 | $87.37 | x |
| 1994-12-31 | $3.98 | $87.37 | x |
| 1995-12-31 | $3.46 | $87.37 | x |
| 1996-12-31 | $3.85 | $87.37 | x |
| 1997-12-31 | $3.60 | $87.37 | x |
| 1998-12-31 | $4.35 | $87.37 | x |
| 1999-12-31 | $6.03 | $87.37 | x |
| 2000-12-31 | $7.16 | $87.37 | x |
| 2001-12-31 | $12.65 | $87.37 | x |
| 2002-12-31 | $9.97 | $87.37 | x |
| 2003-12-31 | $10.44 | $87.37 | x |
| 2004-12-31 | $11.25 | $87.37 | x |
| 2005-12-31 | $12.56 | $87.37 | x |
| 2006-12-31 | $12.53 | $87.37 | x |
| 2007-12-31 | $13.04 | $87.37 | x |
| 2008-12-31 | $13.21 | $87.37 | x |
| 2009-12-31 | $13.97 | $87.37 | x |
| 2010-12-31 | $16.32 | $87.37 | x |
| 2011-12-31 | $16.18 | $87.37 | x |
| 2012-12-31 | $16.89 | $87.37 | x |
| 2013-12-31 | $17.57 | $87.37 | x |
| 2014-12-31 | $17.95 | $87.37 | x |
| 2015-12-31 | $18.62 | $87.37 | x |
| 2016-12-31 | $19.52 | $87.37 | x |
| 2017-12-31 | $22.58 | $87.37 | x |
| 2018-12-31 | $23.18 | $87.37 | x |
| 2019-12-31 | $25.24 | $87.37 | x |
| 2020-12-31 | $33.33 | $87.37 | x |
| 2021-12-31 | $61.21 | $87.37 | x |
| 2022-12-31 | $58.40 | $87.37 | x |
| 2023-12-31 | $63.08 | $87.37 | x |
| 2024-12-31 | $62.42 | $87.37 | x |
| 2025-12-31 | $64.04 | $87.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Revvity Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.46%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.68x
- Recent ROE (3.33%) is below the historical average (10.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 27.38% | 4.82% | 2.69x | 2.11x | $35.36 Million |
| 1986 | 19.00% | 3.92% | 2.57x | 1.88x | $21.27 Million |
| 1987 | 20.45% | 4.49% | 2.40x | 1.90x | $28.36 Million |
| 1988 | 20.67% | 4.89% | 2.61x | 1.62x | $35.47 Million |
| 1989 | 20.03% | 4.24% | 2.56x | 1.84x | $35.00 Million |
| 1990 | 20.02% | 2.99% | 3.66x | 1.83x | $37.04 Million |
| 1991 | 19.30% | 3.02% | 3.85x | 1.66x | $39.13 Million |
| 1992 | 18.54% | 3.15% | 3.72x | 1.58x | $40.44 Million |
| 1993 | 16.67% | 2.95% | 3.51x | 1.61x | $31.85 Million |
| 1994 | -7.21% | -2.41% | 1.68x | 1.78x | $-76.64 Million |
| 1995 | 14.80% | 3.83% | 1.77x | 2.19x | $17.61 Million |
| 1996 | 16.49% | 4.22% | 1.73x | 2.25x | $23.69 Million |
| 1997 | 10.27% | 2.31% | 1.76x | 2.53x | $870.00K |
| 1998 | 25.52% | 7.24% | 1.24x | 2.85x | $62.03 Million |
| 1999 | 5.16% | 2.08% | 0.79x | 3.11x | $-26.68 Million |
| 2000 | 12.43% | 5.34% | 0.77x | 3.00x | $17.68 Million |
| 2001 | -0.05% | -0.05% | 0.45x | 2.18x | $-136.98 Million |
| 2002 | -0.33% | -0.27% | 0.53x | 2.26x | $-129.37 Million |
| 2003 | 3.93% | 3.45% | 0.59x | 1.93x | $-81.95 Million |
| 2004 | 5.20% | 5.31% | 0.55x | 1.76x | $-70.13 Million |
| 2005 | 4.95% | 5.55% | 0.55x | 1.63x | $-83.31 Million |
| 2006 | 7.43% | 7.58% | 0.62x | 1.59x | $-40.62 Million |
| 2007 | 8.44% | 7.44% | 0.61x | 1.87x | $-24.61 Million |
| 2008 | 8.19% | 6.55% | 0.67x | 1.87x | $-28.39 Million |
| 2009 | 5.25% | 5.52% | 0.51x | 1.88x | $-77.30 Million |
| 2010 | 19.94% | 22.53% | 0.53x | 1.67x | $191.38 Million |
| 2011 | 0.06% | 0.06% | 0.50x | 2.09x | $-183.05 Million |
| 2012 | 3.53% | 3.24% | 0.54x | 2.01x | $-125.54 Million |
| 2013 | 8.42% | 7.75% | 0.55x | 1.98x | $-31.52 Million |
| 2014 | 7.74% | 7.06% | 0.54x | 2.02x | $-46.17 Million |
| 2015 | 10.07% | 10.09% | 0.51x | 1.97x | $1.41 Million |
| 2016 | 10.85% | 11.05% | 0.49x | 1.99x | $18.32 Million |
| 2017 | 4.51% | 5.01% | 0.37x | 2.43x | $-137.30 Million |
| 2018 | 9.24% | 8.60% | 0.46x | 2.31x | $-19.71 Million |
| 2019 | 8.09% | 7.89% | 0.44x | 2.32x | $-53.82 Million |
| 2020 | 19.49% | 19.25% | 0.48x | 2.13x | $354.55 Million |
| 2021 | 13.21% | 24.64% | 0.26x | 2.10x | $229.03 Million |
| 2022 | 7.71% | 17.19% | 0.23x | 1.91x | $-169.11 Million |
| 2023 | -1.50% | -4.30% | 0.20x | 1.72x | $-905.65 Million |
| 2024 | 3.86% | 10.74% | 0.22x | 1.62x | $-470.85 Million |
| 2025 | 3.33% | 8.46% | 0.23x | 1.68x | $-483.36 Million |
Industry Comparison
This section compares Revvity Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Revvity Inc. (RVTY) | $7.25 Billion | 27.38% | 0.68x | $8.97 Billion |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |